b7-h3-car t cells
Atypical Teratoid/Rhabdoid Tumor
St. Jude Children's Research HospitalCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Atypical Teratoid/Rhabdoid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tazemetostat Epizyme, Inc. | Phase 2 | B |
Thalidomide Medical University of Vienna | Phase 2 | CCC |
Cyclophosphamide Medical University of Vienna | Phase 2 | CCC |
Fenofibric Acid Medical University of Vienna | Phase 2 | CCC |
ETOPOSIDE Medical University of Vienna | Phase 2 | CCC |
View all 39 →
Same molecule, other indications
b7-h3-car t cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →